Condition: Chronic Kidney Diseases · Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia
Phase III, multicenter, randomized, open-label, parallel-group, non-inferiority, phase III clinical trial comparing CSZ (Lokelma) vs. iSRAA discontinuation/reduction and/or ARM (standard treatment).
This description comes directly from the study's public registry record.
Jose Luis Górriz · +34 96 197 38 11 · jlgorriz@gmail.com
Always discuss trial participation with your own doctor first.
| Hospital General Universitario Dr. Balmis | Alicante, Spain | Recruiting |
| Hospital Universitario Vall d'Hebrón | Barcelona, Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid, Spain | Recruiting |
| Hospital Clínico Universitario de Valencia | Valencia, Spain | Recruiting |
| Hospital Universitario Doctor Peset | Valencia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06578533